2 Small Biotechs with Big Positive Catalysts (The Market Cap)

Our Top Ideas: REITs Raising Dividends in May and Small Biotechs with Big Catalysts

Ensure you continue to get this valuable content by whitelisting us (find out how here).

Wednesday, April 29, 2015 Edit Subscriber Profile  |  Unsubscribe  |  Privacy Policy

Panic! Soda consumption in the US is at its lowest levels in decades. Anti-sugar hysteria has devastated a 180 Billion dollar industry, Coke's earnings are down 40% in less than 5 years. Research a Company poised for potential monstrous gains set to save major beverage companies from disaster. < Click here for a Special Report >

2 Small Biotechs with Big Positive Catalysts By Bret Jensen, Editor of Small Cap Gems One thing that I have developed over the past couple of decades investing in the small biotech space is learning to recognize when a company and its stock start to have positive catalysts happening and also on the horizon. This is critical in spotting potential big winners in the market. In spring of last year I noticed that Avanir Pharmaceuticals had just won a major court victory to retain exclusivity on its primary drug through 2026. The company also had phase II trial results coming up later on in the year for a promising compound to treat the agitation commonly found in Alzheimer's patients. When results turned out to be positive a few months later, the stock shot up. Soon thereafter, the company received a substantial buyout offer from a bigger Japanese-based pharma player in December bringing better than a 215% return to the Small Cap Gems portfolio. Given the huge amount of volatility in the small cap biotech space it is crucial that investors know what if any potential positive catalysts are on the near and medium term horizon for a company when they consider making an investment in a speculative but promising stock in this sector. Here are a couple of small biotech equities that appear to have mounting positive catalysts as well as promising futures. Click to continue reading 2 REITs Raising Dividends in May By Tim Plaehn, Editor of The Dividend Hunter With my dividend and yield focused investment strategy, one of the best moments is getting that email which states that one of my holdings is increasing the company's dividend rate. A stock that pays a stream of steadily growing dividends will produce a total return that works through all stock market cycles. A luxury that many investments cannot afford. The ground floor of the anti-sugar movement... Stevia poised for BIG profits? [ad] With an investment strategy based on dividend growth, you can tailor your portfolio to lean towards current yield, higher dividend growth rates, or a balanced approach. High-yield stocks will have moderate dividend growth rates of a few up to about 5% per year. If you are growth focused, you can find companies that are increasing dividends by 15% to 20% per year and still paying an attractive 2.5% to 4% yield. With these stocks, your total annual returns should average out to the growth rate plus yield. The two stocks I am profiling this week have recent histories of double-digit dividend growth, and I believe that this year is no exception. Click to continue reading

© Copyright 1998-2015, Investors Alley Corp. All rights reserved. See Privacy Policy and Terms of Use | Contact Us

 

If you enjoyed reading this email, click here to forward it to a friend or colleague.

You are receiving this message because you registered ignoble.experiment@arconati.us through INO.com Invite Sell - Apr 2014.
Click here to send us comments or questions regarding this mailing. Unsubscribe/update profile using link below.

This message from Investors Alley Corp. is being sent in full accordance with the CAN-SPAM Act.
We respect your privacy and, therefore, this email was sent directly from Investors Alley.  Please review our Privacy Statement and Terms of Use. 
If you no longer wish to receive emails from Investors Alley, please opt-out using the link below.

The opinions in this email and corresponding web sites are neither an offer nor a recommendation to buy or sell any security. Investors Alley Corp. and its affiliates may hold a position in any of the companies mentioned.  Investors Alley Corp. is not a registered investment firm nor a broker/dealer.  We urge you to always conduct your own research and due diligence and obtain professional advice before making any investment decision.

All information contained herein is copyright 2015, Investors Alley Corp.
Investors Alley Corporation | 41 Madison Avenue | 31st Floor | New York, NY  10010

Update Your Profile Information | Modify Subscription Settings or Unsubscribe From Emails